Business
New contract to support Phase II clinical trial
New contract to support Phase II clinical trial.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 6071S IXICO plc 04 October 2017 \n\n4 October 2017\n \nIXICO plc\n \n(\"IXICO\" or the \"Company\")\n \nIXICO signs new contract to deploy biosensors in a Phase II neurological clinical trial\n \nFirst commercial contract using IXICO's wearable biosensor technology\n \nIXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract, with a top 15 global pharmaceutical company, utilising wrist worn activity sensors ('wearable biosensors') in a Phase II clinical trial for a neurological disorder.\n \nThis is IXICO's first commercial agreement using activity sensors to evaluate exploratory digital measures in early phase clinical research and follows a presentation of IXICO's approach to measuring sleep disturbances at the \"Mobile devices for clinical trials in neurological diseases workshop\" earlier this year at the Clinical Data Interchange Standards Consortium (CDISC) and the Critical Path Institute Coalition Against Major Diseases (CAMD) meetings.\n \nThis contract has a value of around £0.5m over a two year term, commencing in September 2017. IXICO will utilise its biosensor clinical trial capabilities, combined with its artificial intelligence data analytics algorithms, to measure activity and sleep disturbances from biosensor data collected from c.300 people.\n \nSleep disturbance is a challenging symptom of many brain diseases including Parkinson's and Alzheimer's Disease and is also a side effect of many drug treatments. The work performed in this clinical trial, represents an important step in the validation of biosensors as new digital technologies in a specific context of use, as required by regulatory authorities.\n \nGiulio Cerroni, CEO of IXICO, commented: \"We are delighted to be deploying wearable biosensors and our proprietary algorithms to measure sleep disturbance in a commercial clinical trial. This is an excellent opportunity for IXICO to demonstrate how our biosensor services and technology, build upon our well-established expertise in providing regulatory compliant imaging endpoints in clinical trials, to support the process of developing new drugs to treat neurological diseases.\"\n \nFor further information please contact: \n \n\n\n\n\nIXICO plc \nGiulio Cerroni, C...